何首乌经CYP450介导的草药-药物相互作用:基于药代动力学与体外抑制实验
该研究以生何首乌、药典炮制品及九蒸九晒品为对象,用荧光法评估其对7种重组人CYP450的抑制水平,并在大鼠体内研究何首乌对舒林酸和补骨脂素药代动力学的影响。结果表明抑制程度为生品>药典品>九蒸九晒品,生何首乌增加舒林酸暴露,生品与药典品增加补骨脂素暴露,提示何首乌尤其生品经CYP450抑制存在药物相互作用风险。
要点
- 生何首乌对CYP1A2、CYP2B6、CYP2C8、CYP2C19、CYP2D6、CYP3A4抑制程度高于炮制品。
- 生何首乌与药典品可增加大鼠体内补骨脂素暴露,生何首乌增加舒林酸暴露。
- 九蒸九晒炮制可降低何首乌经CYP450抑制所致的相互作用风险。
核心结论
- 何首乌尤其生品经CYP450抑制具有较高的毒性及药物相互作用风险。
- 九蒸九晒炮制从代谢抑制角度体现了何首乌「增效减毒」的科学内涵。
研究设计与样本
- 研究以生何首乌、中国药典炮制品和九蒸九晒炮制品为主要对象。
- 采用荧光技术评估生品与炮制品及其特征化合物对7种重组人CYP450的抑制水平。
- 在大鼠血浆中研究何首乌生品与不同炮制品对舒林酸和补骨脂素药代动力学的影响。
主要发现
- 三种提取物对CYP1A2、CYP2B6、CYP2C8、CYP2C19、CYP2D6和CYP3A4的抑制程度顺序为:生品>药典品>九蒸九晒品。
- 生品与九蒸九晒品对CYP2C9的抑制水平高于药典品。
- 反式-THSG和芦荟大黄素分别选择性抑制CYP3A4和CYP1A2。
- 表儿茶素没食子酸酯主要抑制CYP3A4和CYP1A2,其次为CYP2C8和CYP2C9。
- 染料木素主要抑制CYP3A4,其次为CYP2C9和CYP2C8;大豆苷元也抑制CYP3A4和CYP2C9。
临床怎么用
- 临床使用何首乌尤其生品时,应关注经CYP450介导的草药-药物相互作用风险。
- 与舒林酸等非甾体抗炎药或含补骨脂素药物联用时需谨慎评估。
- 九蒸九晒炮制品对CYP450的抑制程度较低,可能有助于降低相互作用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polygonum multiflorum Thunb. (PM) is well known both in China and other countries of the world for its tonic properties, however, it has lost its former glory due to liver toxicity incidents in recent years. PURPOSE: The purpose of this study is to determine whether the occurrence of herb-drug interaction (HDI) caused by PM is associated with cytochrome P450 (CYP450) based on pharmacokinetic studies and in vitro inhibition assays. The objective was to provide a reference for the rational and safe use of drugs in clinical practice. METHODS: In this study, raw PM (R), together with its two processed products which included PM by Chinese Pharmacopoeia (M) and PM by "nine cycles of steaming and sunning (NCSS)" ("9"), were prepared as the main research objects. A method based on fluorescence technology was used to evaluate the inhibition levels of raw and processed PMs, as well as corresponding characteristic compounds on seven recombinant human cytochrome P450s (rhCYP450s). The pharmacokinetics of sulindac (a representative of commonly used nonsteroidal anti-inflammatory drugs) and psoralen (a major compound of Psoralea in combination with PM) in rat plasma were studied when combined with raw and different processed products of PM. RESULTS: The inhibitory level order of the three extracts on major different subtypes of CYP450 (CYP1A2, CYP2B6, CYP2C8, CYP2C19, CYP2D6, and CYP3A4) was: R > M > "9". However, the inhibition level of R and "9" is higher than that of M on CYP2C9. Further studies showed that trans-THSG and emodin could selectively inhibit CYP3A4 and CYP1A2, respectively. Epicatechin gallate mainly inhibited CYP3A4 and CYP1A2, followed by CYP2C8 and CYP2C9. Genistein mainly inhibited CYP3A4, followed by CYP2C9 and CYP2C8. CYP3A4 and CYP2C9 were also inhibited by daidzein. The inhibitory effects of all the PM extracts were associated with their characteristic compounds. The results of HDI showed that R increased sulindac exposure to rat blood, and R and M increased psoralen exposure to rat blood, which were consistent with corresponding metabolic enzymes. Overall, the in vitro and in vivo results indicated that PM, especially R, would be at high risk to cause toxicity and drug interactions via CYP450 inhibition. CONCLUSION: This study not only elucidates the scientific connotation of "efficiency enhancement and toxicity reduction" of PM by NCSS from the perspective of metabolic inhibition but also contributes to HDI prediction and appropriate clinical medication of PM.
引用
- Xing Y, Yu Q, Zhou L, et al. Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays. Phytomedicine. 2023. PMID: 36805481. doi:10.1016/j.phymed.2023.154710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。